Non-coding Sequences Which Control Transcription Or Translation Processes (e.g., Promoters, Operators, Enhancers, Ribosome Binding Sites, Etc.) Patents (Class 536/24.1)
-
Publication number: 20150057330Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.Type: ApplicationFiled: March 24, 2014Publication date: February 26, 2015Applicant: The University of Western AustraliaInventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
-
Publication number: 20150059021Abstract: Identification of new enhancer sequence has significant utility in the plant functional genomics. The sugarcane bacilliform badnavirus (SCBV) transcriptional enhancer has been identified. This enhancer can be used to increase the rate of transcription from gene promoters and in activation tagging experiments. A ten-fold increase in transcription was observed when a 4× array of the SCBV enhancer was placed upstream of a truncated form of the maize alcohol dehydrogenase minimal promoter. Methods of using the SCBV transcriptional enhancer are described, as are chimeric transcription regulatory regions, constructs, cells, tissues, and organisms that comprise one or more copies of the enhancer.Type: ApplicationFiled: February 28, 2013Publication date: February 26, 2015Inventors: Patricia Ann Owens Merlo, Cory Larsen, Scott A. Bevan, John P. Davies, Vaka S. Reddy, William Michael Ainley, Mark Allen Thompson
-
Patent number: 8962586Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Pyrroline-5-carboxylate reductase 1 (PYCR1), in particular, by targeting natural antisense polynucleotides of Pyrroline-5-carboxylate reductase 1 (PYCR1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of PYCR1.Type: GrantFiled: February 21, 2011Date of Patent: February 24, 2015Assignee: CuRNA, Inc.Inventors: Joseph Collard, Olga Khorkova Sherman
-
Patent number: 8962916Abstract: The present disclosure provides compositions and methods for regulating expression of heterologous nucleotide sequences in a plant. Compositions include a novel nucleotide sequence for a promoter. A method for expressing a heterologous nucleotide sequence in a plant using the promoter sequence disclosed herein is provided. The method comprises stably incorporating into the genome of a plant cell a nucleotide sequence operably linked to the promoter of the present invention and regenerating a stably transformed plant that expresses the nucleotide sequence.Type: GrantFiled: December 19, 2011Date of Patent: February 24, 2015Assignees: Pioneer Hi Bred International Inc, E I Du Pont de Nemours and CompanyInventors: Scott Diehn, Albert L. Lu, Carl R. Simmons
-
Patent number: 8957196Abstract: Disclosed herein is an inducible high-expression cassette comprising a dihydrofolate reductase (DHFR) promoter from which GC-rich repeat sequences are partially or entirely removed, the cassette capable of more effectively improving a gene amplification system. Also disclosed are an expression vector comprising the inducible expression cassette and optionally a gene encoding a recombinant protein of interest, an animal cell line transformed with the expression vector, and a method of mass producing and purifying a recombinant protein by culturing the transformant. The present invention enables the shortening of the time required to establish a cell line producing a recombinant protein of interest at high levels using a low concentration of a DHFR inhibitor, thereby allowing more effective production of the recombinant protein.Type: GrantFiled: October 16, 2007Date of Patent: February 17, 2015Assignee: Hanmi Science Co., Ltd.Inventors: In Young Choi, Chang Hwan Kim, Hyun Ji Lee, Seong Hee Park, Se Chang Kwon, Gwan Sun Lee
-
Patent number: 8957044Abstract: The present invention provides compositions and methods for treating a myopathy. In certain embodiments, the invention provides compositions and methods for treating, improving muscle function, and prolonging survival in a subject with X-linked myotubular myopathy (XLMTM). The present invention provides a method comprising systemic administration of a composition that induces the increased expression of myotubularin in the muscle of a subject. The invention provides sustained regional and global increases in muscle function.Type: GrantFiled: February 28, 2014Date of Patent: February 17, 2015Assignees: Wake Forest University Health Sciences, Genethon, Children's Medical Center CorporationInventors: Martin K. Childers, Alan H. Beggs, Ana Maria Buj Bello
-
Patent number: 8956829Abstract: Expression vector systems are provided for increased production of a recombinant GDF-5 (rhGDF-5) protein. Also provided are transformed host cells that were engineered to produce and express high levels of rhGDF-5 protein. Methods for production and high expression of rhGDF-5 protein are disclosed herein. The methods of enhancing production and protein expression of rhGDF-5 protein as disclosed are cost-effective, time-saving and are of manufacturing quality.Type: GrantFiled: January 25, 2013Date of Patent: February 17, 2015Assignee: Warsaw Orthopedic, Inc.Inventors: David S. Scher, Roger E. Harrington
-
Patent number: 8957038Abstract: This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering RNA (iRNA) agent capable of decreasing expression of a target RNA associated with the neurological disorder. The methods of the invention include determining an effective amount of a therapeutic composition by introducing a solution containing a tracer into the brain of a mammal. The tracing solution is monitored until a target volume of distribution at steady state distribution is substantially achieved, and the rate of delivery of the therapeutic composition is determined. The therapeutic composition can then be administered at the rate determined by use of the tracing solution.Type: GrantFiled: July 15, 2010Date of Patent: February 17, 2015Assignee: Medtronic, Inc.Inventors: Dinah W. Y. Sah, Andrei P. Guzaev, Matthew H. Adams, Pei Ge, Muthiah Manoharan, Douglas Ulen Gwost, Gregory Robert Stewart, David Kent Stiles, Brian Dale Nelson, William Frederick Kaemmerer, Don Marshall Gash
-
Publication number: 20150044187Abstract: Herein are described a set of novel specific human enhancers for specific forebrain cell types used to study and select for human neural progenitor cells. This approach enables the ability to generate interneurons from human ES, iPS and iN cells, making them available for human transplantation and for molecular/cellular analyses. These approaches are also directly applicable to generating other neuronal cell types, such as cortical and striatal projection neurons, which have implications for many human diseases.Type: ApplicationFiled: October 10, 2014Publication date: February 12, 2015Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Axel Visel, John L.R. Rubenstein, Ying-Jiun (aka, Jasmine) Chen, Len A. Pennacchio
-
Patent number: 8951984Abstract: The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a microRNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics.Type: GrantFiled: April 7, 2014Date of Patent: February 10, 2015Assignee: MirrX Therapeutics A/SInventor: Thorleif Møller
-
Patent number: 8951745Abstract: The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4 (=R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein.Type: GrantFiled: April 4, 2014Date of Patent: February 10, 2015Assignee: Deutsches KrebsforschungszentrumInventors: Christof Niehrs, Wei Wu, Andrey Glinka, Olga Kazanskaya
-
Patent number: 8952145Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.Type: GrantFiled: March 7, 2013Date of Patent: February 10, 2015Assignee: Isis Pharmaceuticals, Inc.Inventor: Susan M. Freier
-
Patent number: 8951790Abstract: The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (MCS), designated pUHAB. The pUHAB vector comprises a high copy replication origin (ColE1), a drug resistance gene (TK-Hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hCMV/intron). Further, pUHAB comprises a selectable marker conferring resistance to kanamycin in bacterial cells, and a phage f1(+) region. pUHAB can be used to transiently or stably express cloned genes when transfected into mammalian cells. The invention also encompasses kits and host cells and cell lines comprising pUHAB, and methods of producing a recombinant protein using pUHAB.Type: GrantFiled: January 6, 2012Date of Patent: February 10, 2015Assignee: Merck Sharp & Dohme Corp.Inventor: Deba P. Saha
-
Patent number: 8952215Abstract: The present inventors produced transgenic silkworms which comprise a promoter of a DNA encoding a protein specifically expressed in the silk gland and a DNA encoding a recombinant antibody whose expression is regulated directly or indirectly by the promoter, and which secrete the recombinant antibody into the silk gland. The recombinant antibodies produced from the silk gland of the transgenic silkworms were confirmed to be active.Type: GrantFiled: October 18, 2006Date of Patent: February 10, 2015Assignees: Nitto Boseki Co., Ltd., National Institute of Agrobiological SciencesInventors: Toshiki Tamura, Isao Kobayashi, Toshio Kanda, Keiro Uchino, Katsuhiro Katayama, Tatsuya Ohashi, Iwao Kiyokawa, Hisae Arai, Noriyuki Funahashi
-
Patent number: 8951981Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Paraoxonase 1(PON1), in particular, by targeting natural antisense polynucleotides of Paraoxonase 1(PON1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of PON1.Type: GrantFiled: June 16, 2010Date of Patent: February 10, 2015Assignee: CuRNA, Inc.Inventors: Joseph Collard, Olga Khorkova Sherman
-
Patent number: 8952216Abstract: The present invention provides an isolated promoter or an active fragment or derivative thereof capable of conferring selective expression on a gene to which it is operably connected in the endosperm of a developing plant seed and preferably in the basal endosperm transfer layer (BETL) of endosperm. The present invention also provides expression vectors and constructs and transgenic plant cells, plant parts and whole plants comprising the promoter, active fragments and derivatives, and well as methods of modulating one or more plant phenotypes employing the promoter, active fragments and derivatives.Type: GrantFiled: May 12, 2010Date of Patent: February 10, 2015Assignee: BASF Plant Science Company GmbHInventors: German Spangenberg, Ulrik John, Carl Ramage, Huihua Fu
-
Publication number: 20150040252Abstract: The invention relates to isolation of novel ?-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.Type: ApplicationFiled: August 1, 2014Publication date: February 5, 2015Applicant: GENZYME CORPORATIONInventors: Scott D. ESTES, Weiqun ZHANG
-
Publication number: 20150040269Abstract: The invention relates to an isolated cis-regulatory element imparting pathogen inducibility or elicitor inducibility, which comprises a nucleic acid molecule, the nucleotide sequence of which corresponds to one of the core sequence motifs comprising a) vaaagtm, b) aaacca, c) scaaam, d) acrcg, e) sktgkact, f) mrtsack, g) ccaccaa, h) tcgtctcttc (SEQ ID NO: 35), i) wwkgwc or a core sequence motif complementary to a) to i).Type: ApplicationFiled: December 21, 2012Publication date: February 5, 2015Applicant: KWS SAAT AGInventors: Dietmar Stahl, Fridtjof Weltmeoer, Reinhard Hehl, Jeannette Koschmann, Julia Niemeyer
-
Publication number: 20150037800Abstract: Methods of, and compositions for, assembling one or more transcription units in a genome without a linked selectable marker or other unwanted transcription unit are provided. Also provided methods of, and compositions for, assembling one or more transcription units in a genome with a reduced frequency of vector backbone.Type: ApplicationFiled: October 22, 2014Publication date: February 5, 2015Applicant: MONSANTO TECHNOLOGY LLCInventors: Larry A. GILBERTSON, Susan J. JOHNSON
-
Patent number: 8946183Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.Type: GrantFiled: December 19, 2012Date of Patent: February 3, 2015Assignee: Isis Pharmaceuticals, Inc.Inventors: Brenda F. Baker, Adrian R. Krainer, Yimin Hua
-
Patent number: 8945848Abstract: The invention provides for compositions and methods for identifying and validating modulators of cell fate, such as such as maintenance, cell specification, cell determination, induction of stem cell fate, cell differentiation, cell dedifferentiation, and cell trans-differentiation. The invention relates to reporter nucleic acid constructs, host cells comprising such constructs, and methods using such cells and constructs. The invention relates to methods for making cells comprising one or more reporter nucleic acid constructs using fluorogenic oligonucleotides. The methods relate to high throughput screens.Type: GrantFiled: July 30, 2010Date of Patent: February 3, 2015Assignee: Chromocell CorporationInventors: Kambiz Shekdar, Dennis J. Sawchuk, Jessica C. Langer
-
Patent number: 8946399Abstract: The invention relates to a pathogen-inducible synthetic promoter which is suitable for regulating the transcription of a nucleic acid, and includes a minimal promoter, characterized in that the minimal promoter includes a sequence motif a) dbrmwa or b) twcccmt which is disposed downstream from a TATA region and in front of a transcription starting point which is located on the minimal promoter and at which transcription of the nucleic acid to be regulated starts.Type: GrantFiled: June 16, 2007Date of Patent: February 3, 2015Assignee: KWS SAAT AGInventor: Klaus Schmidt
-
Patent number: 8945885Abstract: The present invention provides minicircle nucleic acid vector formulations for use in administering to a subject, wherein the minicircle nucleic acid vectors include a polynucleotide of interest, a product hybrid sequence of a unidirectional site-specific recombinase, and are devoid of plasmid backbone bacterial DNA sequences. Also provided are methods of producing the subject formulations as well as methods for administering the minicircle nucleic acid vector formulations to a subject. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications.Type: GrantFiled: August 6, 2012Date of Patent: February 3, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Zhi-Ying Chen, Mark A. Kay
-
Patent number: 8945530Abstract: The present invention relates to the provision of a DNA sequence of the major grass pollen allergen Lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies.Type: GrantFiled: December 6, 2010Date of Patent: February 3, 2015Assignee: Merck Patent GmbHInventors: Andreas Nandy, Helmut Fiebig, Oliver Cromwell
-
Patent number: 8945531Abstract: A recombinant herpes virus showing high antitumor activity is provided. In particular, a recombinant herpes simplex virus that expresses an ICP6 gene under control of a tumor-specific promoter or tissue-specific promoter on the genome of the virus is provided.Type: GrantFiled: February 19, 2010Date of Patent: February 3, 2015Assignee: The University of TokyoInventors: Tomoki Todo, Hiroshi Fukuhara
-
Patent number: 8945872Abstract: Expression vector systems are provided for increased production of a recombinant GDF-5 (rhGDF-5) protein. Also provided are transformed host cells that were engineered to produce and express high levels of rhGDF-5 protein. Methods for production and high expression of rhGDF-5 protein are disclosed herein. The methods of enhancing production and protein expression of rhGDF-5 protein as disclosed are cost-effective, time-saving and are of manufacturing quality.Type: GrantFiled: January 25, 2013Date of Patent: February 3, 2015Assignee: Warsaw Orthopedic, Inc.Inventors: David S. Scher, Roger E. Harrington
-
Patent number: 8945851Abstract: The present invention relates to a kit for detection of association of a peripheral cellular membrane binding protein with cellular membranes in living cells and methods thereof. The kit includes a first nucleic acid construct comprising a first nucleic acid molecule encoding a first fusion protein comprising a peripheral cellular membrane binding protein or membrane binding domain thereof operatively coupled to DNA binding and transactivation domains of a naturally occurring or chimeric transcription factor and a first promoter operatively associated with the first nucleic acid molecule. A second nucleic acid construct comprises a second nucleic acid molecule encoding a reporter protein and a second promoter responsive to the DNA binding and transactivation domains of the first fusion protein. The second promoter is operatively associated with the second nucleic acid molecule. Activation of the second promoter results in expression of the reporter protein. Also disclosed is a transgenic non-human animal.Type: GrantFiled: August 31, 2011Date of Patent: February 3, 2015Assignee: New York UniversityInventors: Mark R. Philips, Nicole Fehrenbacher, Joseph Wynne
-
Patent number: 8945884Abstract: The present invention provides compositions and methods for recombinational cloning. The compositions include vectors having multiple recombination sites and/or multiple topoisomerase recognition sites. The methods permit the simultaneous cloning of two or more different nucleic acid molecules. In some embodiments the molecules are fused together while in other embodiments the molecules are inserted into distinct sites in a vector. The invention also generally provides for linking or joining through recombination a number of molecules and/or compounds (e.g., chemical compounds, drugs, proteins or peptides, lipids, nucleic acids, carbohydrates, etc.) which may be the same or different.Type: GrantFiled: May 13, 2013Date of Patent: February 3, 2015Assignee: Life Technologies CorporationInventors: Jonathan Chesnut, John Carrino, Louis Leong, Knut Madden, Martin Gleeson, James Fan, Michael Brasch, David Cheo, James Hartley, Devon Byrd, Gary Temple
-
Patent number: 8945839Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.Type: GrantFiled: April 18, 2014Date of Patent: February 3, 2015Assignees: The Broad Institute Inc., Massachusetts Institute of TechnologyInventor: Feng Zhang
-
Patent number: 8946127Abstract: Use of the ssrA gene or tmRNA, an RNA transcript of the ssrA gene, or fragments thereof as target regions in a nucleic acid probe assay for the detection and identification of prokaryotic and/or eukaryotic organisms is described. Nucleotide sequence alignment of tmRNA sequences from various organisms can be used to identify regions of homology and non-homology within the sequences which in turn can be used to design both genus specific and species specific oligonucleotide probes. These newly identified regions of homology and non-homology provide the basis of identifying and detecting organisms at the molecular level. Oligonucleotide probes identified in this way can be used to detect tmRNA in samples thereby giving an indication of the viability of non-viral organisms present in various sample types.Type: GrantFiled: March 4, 2013Date of Patent: February 3, 2015Assignees: Enterprise Ireland, National University of IrelandInventors: Thomas Gerard Barry, Terence James Smith
-
Publication number: 20150031103Abstract: The promoter of the present invention causes a desired gene to be highly expressed, especially in thermotolerant yeast. The promoter is located upstream of the PIR1 gene or the CTR1 gene on the Kluyveromyces marxianus chromosome and comprises a region controlling expression of the PIR1 gene or the CTR1 gene.Type: ApplicationFiled: March 4, 2013Publication date: January 29, 2015Applicants: TOYOTA JIDOSHA KABUSHIKI KAISHA, JX NIPPON OIL & ENERGY CORPORATION, YAMAGUCHI UNIVERSITYInventors: Noriko Shisa, Rinji Akada, Hisashi Hoshida, Kozue Mutaguchi, Takeshi Uemura, Kenro Tokuhiro, Satoshi Katahira
-
Publication number: 20150033417Abstract: The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3? termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait. One of ordinary skill in the art, having this data, can obtain cloned DNA fragments, synthetic DNA fragments or polypeptides constituting desired sequences by recombinant methodology known in the art or described herein.Type: ApplicationFiled: December 3, 2004Publication date: January 29, 2015Inventors: Nickolai Alexandrov, Nestor Apuya, Vyacheslav Brover, Jean-Baptiste Dumas, Yiwen Fang, Ken Feldmann, Diane Jofuku, Edward A. Kiegle, Bill Kimmerly, Shing Kwok, Peter Mascia, Jack Okamuro, Roger Pennell, Richard Schneeberger, Tatiana Tatarinova, Wayne Volkmuth
-
Patent number: 8940962Abstract: The present invention provides novel promoters for use in plants. Specifically, the present invention provides novel chimeric promoters comprising combinations of plant viral enhancer elements and plant promoters. The present invention also provides DNA constructs; transgenic cells, plants, and seeds containing these novel chimeric promoters; and methods for preparing and using the same.Type: GrantFiled: September 21, 2009Date of Patent: January 27, 2015Assignee: Monsanto Technology LLCInventor: Stanislaw Flasinski
-
Patent number: 8940479Abstract: The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-I to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-I protein or a molecule in a signal transduction pathway involving XBP-1.Type: GrantFiled: January 14, 2009Date of Patent: January 27, 2015Assignee: Cornell UniversityInventors: Ann-Hwee Lee, Laurie H. Glimcher
-
Patent number: 8940502Abstract: The present invention relates to methods for producing a polypeptide, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a first polynucleotide comprising a nucleic acid sequence encoding the polypeptide operably linked to a copper-inducible promoter sequence comprising a copper-responsive upstream activation sequence activated by a copper-dependent trans-acting transcription factor and a second polynucleotide comprising one or more (several) additional copper-responsive upstream activation sequences operably linked upstream to the promoter sequence, wherein the promoter sequence is foreign to the nucleic acid sequence encoding the polypeptide and the copper-responsive upstream activation sequences are responsible for copper-induced transcription of the promoter sequence, and a third polynucleotide comprising at least one copy of a gene encoding the copper-dependent trans-acting transcription factor; and (b) isolatType: GrantFiled: July 13, 2007Date of Patent: January 27, 2015Assignees: Novozymes, Inc., Novozymes A/SInventors: Debbie Yaver, Mads Eskelund Bjornvad, Barbara Cherry
-
Publication number: 20150025231Abstract: The present disclosure provides compounds comprising oligonucleotides complementary to a portion of the IKBKAP gene. Certain such compounds are useful for hybridizing to a portion of the IKBKAP gene, including but not limited to a portion of the IKBKAP gene in a cell. In certain embodiments, such hybridization results in modulation of splicing of the IKBKAP gene. In certain embodiments, the IKBKAP gene includes a mutation that results in defective splicing and a truncated IKAP protein. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the IKBKAP gene results in a decrease in the amount of defective splicing and truncated IKAP protein. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the IKBKAP gene results in an increase in the amount of normal splicing and functional, full-length IKAP protein. In certain embodiments, oligonucleotides are used to treat Familial Dysautonomia.Type: ApplicationFiled: January 11, 2013Publication date: January 22, 2015Applicants: COLD SPRING HARBOR LABORATORY, ISIS PHARMACEUTICALS, INC.Inventors: C. Frank Bennett, Frank Rigo, Adrian R. Krainer, Rahul Sinha
-
Publication number: 20150024498Abstract: Isolated polynucleotides comprising a CLDN5 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The mini-promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, etc.Type: ApplicationFiled: February 13, 2014Publication date: January 22, 2015Inventors: Elizabeth M. Simpson, Wyeth W. Wasserman, Daniel Goldowitz, Charles de Leeuw
-
Patent number: 8936937Abstract: Modified expression vectors, including Tobacco Mosaic Virus (TMV) expression vectors, methods for modifying such vectors, and uses of the same are disclosed.Type: GrantFiled: January 28, 2008Date of Patent: January 20, 2015Assignee: The Ohio State University Research FoundationInventor: John A. Lindbo
-
Publication number: 20150020242Abstract: A novel promoter useful for altering the color of flowers of a plant, which is selected from the group consisting of: (1) a nucleic acid which comprises the nucleotide sequence represented by SEQ ID NO: 20, SEQ ID NO: 12 or SEQ ID NO: 21; and (2) a nucleic acid which maintains the same promoter activity as that of the nucleotide sequence represented by SEQ ID NO: 20, SEQ ID NO: 12 or SEQ ID NO: 21, and which comprises a nucleotide sequence that is produced by modifying the original nucleotide sequence by the addition, deletion and/or substitution of one or several nucleotide sequences, or can hybridize with a nucleotide acid comprising a nucleotide sequence complementary to the original nucleotide sequence under highly stringent conditions, or has a 90% or more sequence identity to the original nucleotide sequence.Type: ApplicationFiled: February 19, 2013Publication date: January 15, 2015Applicant: SUNTORY HOLDINGS LIMITEDInventors: Yoshikazu Tanaka, Yukihisa Katsumoto
-
Patent number: 8933215Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: December 3, 2012Date of Patent: January 13, 2015Assignee: Silence Therapeutics Aktiengesellschaft (AG)Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 8933302Abstract: The present invention relates to the isolation of Jatropha curcas curcin genes and tissue-specific promoters and to the production of curcin-deficient Jatropha plants. More specifically, the present invention relates to the isolation of Jatropha curcas Curcin 1, Curcin 2 and Curcin 2 A. The present invention further relates to of the Curcin 1, Curcin 2 A and Curcin 2 genes and more particularly to tissue specific promoters of the Curcin 1 and Curcin 2A genes. The present invention further relates to production of curcin-deficient transgenic jatropha plants by using RNAi technology to suppress curcin gene expression.Type: GrantFiled: June 2, 2010Date of Patent: January 13, 2015Assignee: Temasek Life Sciences Laboratory LiimitedInventors: Zhong Chao Yin, Li Fang Wu, Hui Zhu Mao, Cheng Xiang Qiu
-
Patent number: 8932814Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.Type: GrantFiled: April 22, 2014Date of Patent: January 13, 2015Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: Le Cong, Feng Zhang
-
Patent number: 8933049Abstract: The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-?1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-?1 (i.e., increases the production of IFN-?1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-?1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-?1 protein that promotes an anti-viral response as well as treats asthma diseases and colon diseases.Type: GrantFiled: February 20, 2013Date of Patent: January 13, 2015Assignee: Medical Diagnostic Laboratories, LLCInventors: Grant Gallagher, Rachel Siegel, Joyce Eskdale, Adam Swider
-
Publication number: 20150011407Abstract: The invention refers to a library of bidirectional expression cassettes or expression vectors comprising a repertoire of bidirectional promoter sequences, each expression cassette comprising a promoter sequence operably linked to a first gene in one direction, and operably linked to an oppositely oriented second gene in the other direction which is different from the first gene, and bidirectional Pichia pastoris or CHO cells promoter sequences. The invention further refers to a method of screening or selecting a bidirectional promoter suitable for expressing at least two GOI in a host cell and a kit comprising a) an expression cassette consisting of the first and second genes and a stuffer sequence separating them, which stuffer sequence comprises a recognition site for a type IIS restriction enzyme at both ends; b) the type IIS restriction enzyme; c) and a repertoire of promoter, preferably a promoter library including bidirectional promoters.Type: ApplicationFiled: July 7, 2014Publication date: January 8, 2015Inventors: Thomas VOGL, Thomas KICKENWEIZ, Lukas STURMBERGER, Anton GLIEDER
-
Publication number: 20150010518Abstract: Isolated polynucleotides comprising a NR2E1 mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, gene therapy, etc.Type: ApplicationFiled: June 30, 2014Publication date: January 8, 2015Inventors: Elizabeth M. Simpson, Wyeth W. Wasserman, Daniel Goldowitz, Charles de Leeuw
-
Publication number: 20150011400Abstract: Although metabolic networks have been reconstructed on a genome-scale, the corresponding reconstruction and integration of governing transcriptional regulatory networks has not been fully achieved. Here such an integrated network was constructed for amino acid metabolism in Escherichia coli. Analysis of ChlP-chip and gene expression data for the transcription factors ArgR, Lrp, and TrpR showed that 19/20 amino acid biosynthetic pathways are either directly or indirectly controlled by these regulators. Classifying the regulated genes into three functional categories of transport, biosynthesis, and metabolism leads to elucidation of regulatory motifs constituting the integrated network's basic building blocks. The regulatory logic of these motifs was determined based on the relationships between transcription factor binding and changes in transcript levels in response to exogenous amino acids. Remarkably, the resulting logic shows how amino acids are differentiated as signaling and nutrient molecules.Type: ApplicationFiled: November 9, 2012Publication date: January 8, 2015Inventors: Bernhard Palsson, Byung-kwan Cho
-
Publication number: 20150011007Abstract: Provided herein are nucleic acid constructs that contain a synthetic control element that includes a cis-regulator of translation, and an adapter translation-coupled regulator of transcription. Further provided herein are nucleic acid constructs that contain nucleic acid sequences under the control of the synthetic control elements. Also provided are compositions and methods related to the nucleic acid constructs.Type: ApplicationFiled: September 27, 2012Publication date: January 8, 2015Inventors: Chang Liu, Adam P. Arkin, Lei S. Qi
-
Patent number: 8927269Abstract: The present invention provides an Avian adeno-associated virus (AAAV) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAAV vectors and particles. Methods of isolating the AAAV are provided.Type: GrantFiled: May 18, 2004Date of Patent: January 6, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ioannis Bossis, John A. Chiorini
-
Patent number: 8927519Abstract: Methods for producing interfering RNA molecules in mammalian cells are provided. Therapeutic uses for the expressed molecules, including inhibiting expression of HIV, are also provided.Type: GrantFiled: January 27, 2014Date of Patent: January 6, 2015Assignee: City of HopeInventors: John J. Rossi, Nan-Sook Lee
-
Patent number: 8927702Abstract: The present invention relates to isolated Solanum Bulbocastanum Bul409 promoter sequences and uses thereof. An exemplary embodiment provides an isolated plant Bul409 promoter comprising a nucleic acid sequence that is at least about 90% identical to nucleotides 1-771 of SEQ ID NO:1, wherein the promoter sequence is capable of controlling transcription in a plant. Other exemplary embodiments provide a method for making a transgenic plant, wherein the method comprises transforming a plant, plant part, or plant cell with an expression vector comprising isolated plant Bul409 promoter operably linked to a heterologous nucleic acid sequence, wherein the isolated plant Bul409 promoter is capable of controlling transcription of the heterologous nucleic acid in a plant, and a transgenic plant made by the method and decendants thereof.Type: GrantFiled: June 19, 2007Date of Patent: January 6, 2015Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: William R. Belknap, Sophie S. Chang, David R. Rockhold, Nathaniel T. Taylor, Kent F. McCue